Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-27 · 1381 Präparate · 72104 Quellenpassagen · 204 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Tabrecta
Tabrecta 150 mg film-coated tablets Tabrecta 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 9
HOS-290980 · Präparat HOS-287432
Adverse reactions from clinical studies (Table 3) are listed by MedDRA system organ class. Within
each system organ class, the adverse reactions are ranked by frequency, with the most frequent
reactions first. In addition, the corresponding frequency category for each adverse reaction is based on
the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to
<1/100); rare (≥1/10 000 to <1/1 000); very rare (<1/10 000). Within each frequency grouping,
adverse reactions are presented in the order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-27T12:00:00Z · SHA-256 4d31a541647a5d2f142ab7f81804223c094caed82e0879b8e4c17896418b4a9c · Passage e5e71d8290a7b0b2b51f4bb5435bca4c2636cc23c022e8e647fdf842a47f5d4b · Zeichen 2861–3419 im Abschnitt
Nebenwirkungen · Tabrecta
Tabrecta 150 mg film-coated tablets Tabrecta 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 9
HOS-290981 · Präparat HOS-287432
Table 3 Adverse reactions in patients (N=160) harbouring METex14 skipping mutations in
study GEOMETRY mono-1
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-27T12:00:00Z · SHA-256 4d31a541647a5d2f142ab7f81804223c094caed82e0879b8e4c17896418b4a9c · Passage 34b5483c1a7495519a30f87409bd30ba5647411fa0e7703c03b0dcb27e2aa301 · Zeichen 3421–3547 im Abschnitt
Nebenwirkungen · Tabrecta
Tabrecta 150 mg film-coated tablets Tabrecta 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 9
HOS-290982 · Präparat HOS-287432
Adverse reaction All grades All grades Grade 3/4
Frequency category % %
Infections and infestations
Cellulitis Common 5.6 2.5*
Metabolism and nutrition disorders
Decreased appetite Very common 21.9 1.3*
Respiratory, thoracic, and mediastinal disorders
Dyspnoea Very common 23.8 6.9*
Cough Very common 17.5 0.6*
ILD/pneumonitis1 Common 7.5 4.4*
Gastrointestinal disorders
Vomiting Very common 25.6 0.6*
Nausea Very common 45.0 0.6*
Diarrhoea Very common 16.9 -
Constipation Very common 13.1 1.3*
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-27T12:00:00Z · SHA-256 4d31a541647a5d2f142ab7f81804223c094caed82e0879b8e4c17896418b4a9c · Passage e427a57ac532dd2c946637c78d420acf5b2e5df21b3cef491eae9c96fa711327 · Zeichen 3550–4756 im Abschnitt
Nebenwirkungen · Tabrecta
Tabrecta 150 mg film-coated tablets Tabrecta 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 9–10
HOS-290983 · Präparat HOS-287432
9
Immune system disorders
Hypersensitivity† Uncommon 0.3 0.3
Skin and subcutaneous tissue disorders
Pruritus Very common 10.6 0.6*
Rash 2 Very common 10.0 -
Urticaria Common 2.5 0.6*
General disorders and administration site conditions
Oedema peripheral3 Very common 68.1 17.5*
Pyrexia 4 Very common 11.9 1.3*
Fatigue5 Very common 35.6 8.8*
Back pain Very common 21.3 1.3*
Weight decreased Very common 12.5 -
Non-cardiac chest pain6 Common 9.4 1.3*
Investigations
Albumin decreased Very common 78.3 1.9*
Creatinine increased Very common 74.5 0.6*
Alanine aminotransferase increased Very common 45.9 11.5
Amylase increased Very common 37.2 7.1
Lipase increased Very common 33.3 11.5
Aspartate aminotransferase increased Very common 33.8 5.7
Phosphate decreased Very common 30.1 4.5
Sodium decreased Very common 22.9 4.5
Bilirubin increased Common 8.3 0.6*
1 ILD/pneumonitis includes preferred terms (PTs) of ILD, pneumonitis and organising
pneumonia.
2 Rash includes PTs of rash, rash maculopapular and rash vesicular.
3 Oedema peripheral includes PTs of oedema peripheral and peripheral swelling.
4 Pyrexia includes PTs of body temperature increased and pyrexia.
5 Fatigue includes PTs of fatigue and asthenia.
6 Non-cardiac chest pain includes PTs of chest discomfort, musculoskeletal chest pain and non-
cardiac chest pain.
* No grade 4 adverse reactions reported in GEOMETRY mono-1 patients with METex14
skipping mutations.
† Hypersensitivity has been observed in solid tumour patients treated with Tabrecta
monotherapy (N=580). Hypersensitivity has also been observed in the post-marketing setting
and in expanded access programmes with Tabrecta.
Cases of acute kidney injury (n=1), renal failure (n=4) and acute pancreatitis (n=1) were reported in
GEOMETRY mono-1 MET-amplified patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-27T12:00:00Z · SHA-256 4d31a541647a5d2f142ab7f81804223c094caed82e0879b8e4c17896418b4a9c · Passage 198936252a9c631784ab0cb60d47ede541dbc7c44762f30160401be3e042b678 · Zeichen 4811–7817 im Abschnitt
Nebenwirkungen · Tabrecta
Tabrecta 150 mg film-coated tablets Tabrecta 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 10
HOS-290984 · Präparat HOS-287432
Description of selected adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-27T12:00:00Z · SHA-256 4d31a541647a5d2f142ab7f81804223c094caed82e0879b8e4c17896418b4a9c · Passage f66db2a8100a521c1dea72ff90e696fa3846f9d5fcd6cf8e5e03ce5d71bde4a7 · Zeichen 7819–7860 im Abschnitt
Nebenwirkungen · Tabrecta
Tabrecta 150 mg film-coated tablets Tabrecta 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 10
HOS-290985 · Präparat HOS-287432
ILD/pneumonitis
Any grade ILD/pneumonitis was reported in 12 of 160 patients (7.5%). Grade 3 ILD/pneumonitis was
reported in 7 patients (4.4%), with one fatal event of treatment-related pneumonitis (0.6%) and one
fatal event of organising pneumonia (0.6%). ILD/pneumonitis occurred in 6 of 63 patients (9.5%) with
a history of prior radiotherapy and 6 of 97 patients (6.2%) who did not receive prior radiotherapy. Six
patients (3.8%) discontinued Tabrecta due to ILD/pneumonitis. ILD/pneumonitis mostly occurred
within approximately the first 3 months of treatment. The median time-to-onset of grade 3 or higher
ILD/pneumonitis was 7.9 weeks (range: 0.7 to 88.4 weeks).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-27T12:00:00Z · SHA-256 4d31a541647a5d2f142ab7f81804223c094caed82e0879b8e4c17896418b4a9c · Passage 39c6415c7daec5bee57c551e9ad5c4ee8a2227c887786966c0f4c41a78598ebe · Zeichen 7862–8531 im Abschnitt
Nebenwirkungen · Tabrecta
Tabrecta 150 mg film-coated tablets Tabrecta 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 10
HOS-290986 · Präparat HOS-287432
Hepatic effects
Any grade ALT/AST elevations were reported in 24 of 160 patients (15.0%). Grade 3 or 4 ALT/AST
elevations were observed in 13 of 160 patients (8.1%) treated with Tabrecta. Three patients (1.9%)
discontinued Tabrecta due to ALT/AST elevations. ALT/AST elevations mostly occurred within
approximately the first 3 months of treatment. The median time-to-onset of grade 3 or higher
ALT/AST elevations was 6.4 weeks (range: 2.1 to 17.9 weeks).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-27T12:00:00Z · SHA-256 4d31a541647a5d2f142ab7f81804223c094caed82e0879b8e4c17896418b4a9c · Passage 29147abfd83be26e017363620c188ebb6c313c2fe7685eeec978afcf5627bf5b · Zeichen 8533–8987 im Abschnitt
Nebenwirkungen · Tabrecta
Tabrecta 150 mg film-coated tablets Tabrecta 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 10–11
HOS-290987 · Präparat HOS-287432
10
Elevations of pancreatic enzymes
Any grade amylase/lipase elevations were reported in 27 of 160 patients (16.9%). Grade 3 or 4
amylase/lipase elevations were reported in 18 of 160 patients (11.3%) treated with Tabrecta. Three
patients (1.9%) discontinued Tabrecta due to amylase/lipase elevations. The median time to onset of
grade 3 or higher amylase/lipase elevations was 10.1 weeks (range: 2.3 to 68.0 weeks).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-27T12:00:00Z · SHA-256 4d31a541647a5d2f142ab7f81804223c094caed82e0879b8e4c17896418b4a9c · Passage 8b0bcecf2013f9725c6fe5a2aeb6bdc23a33b7b3ad92b1b4320b1b268e0f96bc · Zeichen 9039–9455 im Abschnitt
Nebenwirkungen · Tabrecta
Tabrecta 150 mg film-coated tablets Tabrecta 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11
HOS-290988 · Präparat HOS-287432
Peripheral oedema
Any grade peripheral oedema was reported in 109 of 160 patients (68.1%). This adverse reaction
includes the PTs of peripheral oedema, which was the most frequent at 65.6% and peripheral swelling
which occurred in 4.4% of patients. Grade 3 or 4 peripheral oedema was reported in 28 of 160 patients
(17.5%) treated with Tabrecta. Four patients (2.5%) discontinued Tabrecta due to peripheral oedema.
The median time to onset of grade 3 or higher peripheral oedema was 30.1 weeks (range: 1.4 to
219.1 weeks).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-27T12:00:00Z · SHA-256 4d31a541647a5d2f142ab7f81804223c094caed82e0879b8e4c17896418b4a9c · Passage 14038f4644bc9cbce8cb4d0baf864a5ab3c68c2a3bcb407bf835987242bf1efc · Zeichen 9457–9979 im Abschnitt
Nebenwirkungen · Tabrecta
Tabrecta 150 mg film-coated tablets Tabrecta 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11
HOS-290989 · Präparat HOS-287432
Special populations
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-27T12:00:00Z · SHA-256 4d31a541647a5d2f142ab7f81804223c094caed82e0879b8e4c17896418b4a9c · Passage aff3e9efab65f7283de9c5cbb6a63f191f8aa790437b98aa9413380c55f2c310 · Zeichen 9981–10000 im Abschnitt
Nebenwirkungen · Tabrecta
Tabrecta 150 mg film-coated tablets Tabrecta 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11
HOS-290990 · Präparat HOS-287432
Elderly
Of the 160 patients with METex14 skipping mutations in the GEOMETRY mono-1 study who
received 400 mg capmatinib twice daily, 85% were 65 years or older, and 4.4% were 85 years or
older. The occurrence of grade ≥3 events increased with age. Treatment-related serious events were
more frequent in patients aged ≥65 to <75 years (23.2%) and those aged ≥85 years (28.6%) when
compared to those patients aged ≥75 to <85 years (8.5%) and patients younger than 65 years (8.3%),
although this comparison is limited by the small sample size in patients aged ≥85 years.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-27T12:00:00Z · SHA-256 4d31a541647a5d2f142ab7f81804223c094caed82e0879b8e4c17896418b4a9c · Passage 62cdb6c73a7c72620d57c34cd89b0aa240e73e258459312008e4d9ddbfaf9cfb · Zeichen 10002–10569 im Abschnitt
Nebenwirkungen · Tabrecta
Tabrecta 150 mg film-coated tablets Tabrecta 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11
HOS-290991 · Präparat HOS-287432
Reporting of suspected adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-27T12:00:00Z · SHA-256 4d31a541647a5d2f142ab7f81804223c094caed82e0879b8e4c17896418b4a9c · Passage 822da43363cee11e87abeb55cf82453415269315377df150bb5de7dde8dd938f · Zeichen 10571–10611 im Abschnitt
Nebenwirkungen · Tabrecta
Tabrecta 150 mg film-coated tablets Tabrecta 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11
HOS-290992 · Präparat HOS-287432
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system
listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-27T12:00:00Z · SHA-256 4d31a541647a5d2f142ab7f81804223c094caed82e0879b8e4c17896418b4a9c · Passage 591ce3aa6d6555db7032d0551da929e990b92080da2928085827a75c666ec353 · Zeichen 10613–10927 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.